EUHASS: The European haemophilia safety surveillance system

M. Makris; G. Calizzani; K. Fischer; E. A. Gilman; C. R M Hay; R. Lassila; T. Lambert; C. A. Ludlam; P. M. Mannucci

doi:10.1016/S0049-3848(10)70150-X

EUHASS: The European haemophilia safety surveillance system

M. Makris, G. Calizzani, K. Fischer, E. A. Gilman, C. R M Hay, R. Lassila, T. Lambert, C. A. Ludlam, P. M. Mannucci

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Pharmacovigilance is an essential element of any drug treatment and considering the history of adverse events due to products used to treat inherited bleeding disorders, it should be an integral component of modern haemophilia treatment. Because inherited bleeding disorders and adverse events are rare, a multicentre, preferably multinational, adverse event reporting scheme for all clotting factor products is required. EUHASS is a European, prospective, multicentre adverse event reporting scheme in the field of inherited bleeding disorders.

Original language	English
Journal	Thrombosis Research
Volume	127
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1016/S0049-3848(10)70150-X
Publication status	Published - Jan 2011

Keywords

Adverse events
Haemophilia
Inhibitor
Thrombosis

ASJC Scopus subject areas

Hematology

Access to Document

10.1016/S0049-3848(10)70150-X

Cite this

@article{ac2c6b7742d14b0a8b44b6948dfcc1e0,

title = "EUHASS: The European haemophilia safety surveillance system",

abstract = "Pharmacovigilance is an essential element of any drug treatment and considering the history of adverse events due to products used to treat inherited bleeding disorders, it should be an integral component of modern haemophilia treatment. Because inherited bleeding disorders and adverse events are rare, a multicentre, preferably multinational, adverse event reporting scheme for all clotting factor products is required. EUHASS is a European, prospective, multicentre adverse event reporting scheme in the field of inherited bleeding disorders.",

keywords = "Adverse events, Haemophilia, Inhibitor, Thrombosis",

author = "M. Makris and G. Calizzani and K. Fischer and Gilman, {E. A.} and Hay, {C. R M} and R. Lassila and T. Lambert and Ludlam, {C. A.} and Mannucci, {P. M.}",

year = "2011",

month = jan,

doi = "10.1016/S0049-3848(10)70150-X",

language = "English",

volume = "127",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier Limited",

number = "SUPPL. 2",

}

TY - JOUR

T1 - EUHASS

T2 - The European haemophilia safety surveillance system

AU - Makris, M.

AU - Calizzani, G.

AU - Fischer, K.

AU - Gilman, E. A.

AU - Hay, C. R M

AU - Lassila, R.

AU - Lambert, T.

AU - Ludlam, C. A.

AU - Mannucci, P. M.

PY - 2011/1

Y1 - 2011/1

N2 - Pharmacovigilance is an essential element of any drug treatment and considering the history of adverse events due to products used to treat inherited bleeding disorders, it should be an integral component of modern haemophilia treatment. Because inherited bleeding disorders and adverse events are rare, a multicentre, preferably multinational, adverse event reporting scheme for all clotting factor products is required. EUHASS is a European, prospective, multicentre adverse event reporting scheme in the field of inherited bleeding disorders.

AB - Pharmacovigilance is an essential element of any drug treatment and considering the history of adverse events due to products used to treat inherited bleeding disorders, it should be an integral component of modern haemophilia treatment. Because inherited bleeding disorders and adverse events are rare, a multicentre, preferably multinational, adverse event reporting scheme for all clotting factor products is required. EUHASS is a European, prospective, multicentre adverse event reporting scheme in the field of inherited bleeding disorders.

KW - Adverse events

KW - Haemophilia

KW - Inhibitor

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=78650784094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650784094&partnerID=8YFLogxK

U2 - 10.1016/S0049-3848(10)70150-X

DO - 10.1016/S0049-3848(10)70150-X

M3 - Article

C2 - 21193110

AN - SCOPUS:78650784094

SN - 0049-3848

VL - 127

JO - Thrombosis Research

JF - Thrombosis Research

IS - SUPPL. 2

ER -

EUHASS: The European haemophilia safety surveillance system

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this